KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Equity Average (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Equity Average for 8 consecutive years, with -$436.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Equity Average rose 8.22% year-over-year to -$436.8 million, compared with a TTM value of -$436.8 million through Jun 2025, up 8.22%, and an annual FY2025 reading of -$297.5 million, up 36.11% over the prior year.
  • Equity Average was -$436.8 million for Q2 2025 at Biocryst Pharmaceuticals, up from -$463.9 million in the prior quarter.
  • Across five years, Equity Average topped out at -$132.1 million in Q1 2023 and bottomed at -$475.9 million in Q2 2024.
  • Average Equity Average over 3 years is -$411.0 million, with a median of -$450.3 million recorded in 2025.
  • The sharpest move saw Equity Average crashed 252.59% in 2024, then increased 8.22% in 2025.
  • Year by year, Equity Average stood at -$433.3 million in 2023, then fell by 9.0% to -$472.2 million in 2024, then increased by 7.51% to -$436.8 million in 2025.
  • Business Quant data shows Equity Average for BCRX at -$436.8 million in Q2 2025, -$463.9 million in Q1 2025, and -$472.2 million in Q4 2024.